Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Lantheus Medical Imaging to release flurpiridaz F 18 Phase 2 data

Lantheus Medical Imaging is set to release full data of Phase 2 clinical trial to assess the myocardial perfusion using positron emission tomography (PET) imaging of flurpiridaz F 18 in patients with suspected or known coronary artery disease (CAD).

Flurpiridaz F 18 injection, a fluorine 18-labeled agent that binds to mitochondrial complex 1 (MC-1), was designed to be a myocardial perfusion PET imaging agent for the diagnosis of CAD.

In March 2011, Lantheus received special protocol assessment approval from the US Food and Drug Administration for the Phase 3 trial of flurpiridaz F 18.

The primary objective of the study will be to evaluate the sensitivity and specificity of PET imaging with flurpiridaz F 18 as compared to SPECT imaging.

Lantheus Medical Imaging president and CEO Don Kiepert said PET myocardial perfusion imaging with flurpiridaz F 18 has the potential to evaluate patients with known or suspected coronary artery disease than SPECT imaging, and they look forward to initiate phase 3 clinical trials of this new clinical tool in the second quarter of this year.